Perkins Capital Management Inc Immuno Gen, Inc. Transaction History

Perkins Capital Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 22, 2024	SELL	$12.46 - $29.95 $21,182 - $50,915	-1,700 Reduced 14.05%	10,400 $308,000
Q3 2023 Nov 02, 2023	SELL	$14.09 - $19.87 $71,859 - $101,337	-5,100 Reduced 29.65%	12,100 $192,000
Q2 2023 Jul 21, 2023	SELL	$3.75 - $20.05 $16,125 - $86,215	-4,300 Reduced 20.0%	17,200 $325,000
Q1 2023 May 09, 2023	BUY	$3.67 - $4.92 $33,030 - $44,280	9,000 Added 72.0%	21,500 $83,000
Q4 2022 Jan 26, 2023	BUY	$4.55 - $6.31 $56,875 - $78,875	12,500 New	12,500 $62,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Perkins Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Perkins Capital Management Inc with notifications on news.